Login
Israel-Hamas Conflict
BRICS
Floods
Natural Disasters
Social Media
Formula 1
Drones
Amazon
Artificial Intelligence
Donald Trump
Music
Cricket
TikTok
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

New Research Highlights Zabalafin Hydrogel's Novel Multi-Targeted Approach to AD Treatment

Summary by dermatologytimes.com
A new paper highlights Alphyn Biologics' Zabalafin Hydrogel as a promising multi-target therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
dermatologytimes.comdermatologytimes.com

New Research Highlights Zabalafin Hydrogel's Novel Multi-Targeted Approach to AD Treatment

A new paper highlights Alphyn Biologics' Zabalafin Hydrogel as a promising multi-target therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

dermatologytimes.com broke the news in on Wednesday, July 2, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal